Cell therapy and regenerative medicine. Glossary Ingestion-build-86103 Managers responsible for risk

Managers responsible for risk

BS EN 61000-4-4:2012 supersedes BS EN 61000-4-4:2004+A1:2010 which is withdrawn

Management responsibilities

11 Test methods

Publicly Available Specification (PAS) 2060 sets out general requirements for anyone who wants to achieve and show carbon neutrality

Cell therapy and regenerative medicine. Glossary Ingestion-build-86103 Managers responsible for risk1 Scope This PAS lists terms and definitions: a) associated with the naming of types of cell therapy and regenerative medicine products; and b) that describe materials, processes, methodologies and applications within cell therapies and regenerative medicine. It covers: i) general terms; ii) cell and tissue components; iii) non cellular components; iv) cell and tissue procurement; v) measurement and analysis; vi) manufacturing and production; and vii)